Text Size

Acute Comfort and Blur of Systane and Optive

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Alcon Research
ClinicalTrials.gov Identifier:
NCT00568386
First received: December 5, 2007
Last updated: January 31, 2012
Last verified: January 2012
History of Changes
Results First Received: December 18, 2008  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Crossover Assignment;   Masking: Double-Blind;   Primary Purpose: Treatment
Condition: Dry Eye
Interventions: Other: Systane Lubricant Eye Drops
Other: Optive Lubricant Eye Drops

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Medical Clinic Nov. 2007

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
24 hr. wash out between treatment periods

Reporting Groups
  Description
Systane Drops Then Optive Drops Systane Drops then Optive Drops
Optive Drops Then Systane Drops Optive Drops then Systane Drops

Participant Flow:   Overall Study
    Systane Drops Then Optive Drops     Optive Drops Then Systane Drops  
STARTED     20     20  
COMPLETED     20     20  
NOT COMPLETED     0     0  



  Baseline Characteristics
  Hide Baseline Characteristics

Reporting Groups
  Description
Systane Drops Then Optive Drops Systane Drops then Optive Drops
Optive Drops Then Systane Drops Optive Drops then Systane Drops
Total Total of all reporting groups

Baseline Measures
    Systane Drops Then Optive Drops     Optive Drops Then Systane Drops     Total  
Number of Participants  
[units: participants]
 		  20     20     40  
Age  
[units: participants]
 		     
<=18 years     0     0     0  
Between 18 and 65 years     20     20     40  
>=65 years     0     0     0  
Gender  
[units: participants]
 		     
Female     17     17     34  
Male     3     3     6  
Region of Enrollment  
[units: participants]
 		     
United States     20     20     40  



  Outcome Measures

1.  Primary:   Visual Blur   [ Time Frame: 3 minutes post dose ]
  Show Outcome Measure 1


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Alcon Clinical
Organization: Alcon Research
phone: 888.451.3937; 817.568.6725
e-mail: medinfo@alconlabs.com


No publications provided


Responsible Party: Alcon Research
ClinicalTrials.gov Identifier: NCT00568386     History of Changes
Other Study ID Numbers: M-07-02
Study First Received: December 5, 2007
Results First Received: December 18, 2008
Last Updated: January 31, 2012
Health Authority: United States: Institutional Review Board